Investing.com - Aslan Pharma ADR reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of -0.12 on revenue of 0.00. Analysts polled by Investing.com anticipated EPS of -0.105 on revenue of 0.00.
Aslan Pharma ADR shares are down 13.19% from the beginning of the year and are trading at 2.730 , down-from-52-week-high.They are under-performing the Nikkei 225 which is up 2.56% from the start of the year.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings beat by J&J on Tuesday, April 20, 2021, who reported EPS of 2.59 on revenue of 22.32B, compared to forecasts EPS of 2.34 on revenue of 21.98B.
Pfizer had beat expectations on Tuesday, May 4, 2021 with first quarter EPS of 0.93 on revenue of 14.58B, compared to forecast for EPS of 0.7759 on revenue of 13.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar